• 1
    Maisonneuve P, Agodoa L, Gillert R et al. Cancer in patients on dialysis for end stage renal disease: an international collaborative study. Lancet 1999; 354: 9399.
  • 2
    Cooper GS, Yuan Z, Strange KC et al. The sensitivity of Medicare claims data for case ascertainment of six common cancers. Med Care 1999; 37: 436444.
  • 3
    Chapman JR, Sheil AG, Disney AP. Recurrence of cancer after renal transplantation. Transplant Proc 2001; 33: 18301831.
  • 4
    Oberbauer R, Kreis H, Johnson RW et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 2003; 76: 364370.
  • 5
    Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003; 76: 12891293.
  • 6
    Dantal J, Hourmant M, Cantarovich D et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623628.